Difference between revisions of "Adenosquamous carcinoma of the lung"
Jump to navigation
Jump to search
| Line 1: | Line 1: | ||
{{ Infobox diagnosis | {{ Infobox diagnosis | ||
| Name = {{PAGENAME}} | | Name = {{PAGENAME}} | ||
| Image = | | Image = Adenosquamous carcinoma of lung -- high mag.jpg | ||
| Width = | | Width = | ||
| Caption = | | Caption = Adenosquamous carcinoma of lung. [[H&E stain]]. | ||
| Synonyms = | | Synonyms = | ||
| Micro = | | Micro = | ||
Revision as of 05:33, 29 December 2015
| Adenosquamous carcinoma of the lung | |
|---|---|
| Diagnosis in short | |
 Adenosquamous carcinoma of lung. H&E stain. | |
| LM DDx | squamous cell carcinoma of the lung, adenocarcinoma of the lung |
| Site | lung - see lung tumours |
|
| |
| Prevalence | rare |
| Clin. DDx | other lung tumours |
Adenosquamous carcinoma of the lung, also lung adenosquamous carcinoma, is a rare epithelial derived malignancy of the lung with features of both adenocarcinoma and squamous cell carcinoma.
It is grouped with the non-small cell lung cancers.
General
- Rare.
- Respond to tyrosine kinase inhibitors.[1][2]
Microscopic
Features:
- Adenocarcinoma component.
- Squamous cell carcinoma component.
Images
www:
- Lung adenosquamous carcinoma (webpathology.com).
- Lung adenosquamous carcinoma (flickr.com/Yale Rosen).
See also
References
- ↑ Song, Z.; Lin, B.; Shao, L.; Zhang, Y. (Sep 2013). "Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma.". J Chin Med Assoc 76 (9): 481-5. doi:10.1016/j.jcma.2013.05.007. PMID 23769878.
- ↑ Iwanaga, K.; Sueoka-Aragane, N.; Nakamura, T.; Mori, D.; Kimura, S. (2012). "The long-term survival of a patient with adenosquamous lung carcinoma harboring EGFR-activating mutations who was treated with gefitinib.". Intern Med 51 (19): 2771-4. PMID 23037472.